RecruitingPhase 1NCT04478305

Affect of Duavive on Mood & Anxiety Symptoms

The Effect of Conjugated Estrogens/ Bazedoxifene (CE/ BZA) on Peri- and Postmenopausal Mood and Anxiety Symptoms: A Pilot Study


Sponsor

St. Joseph's Healthcare Hamilton

Enrollment

30 participants

Start Date

Jul 3, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study evaluates the impact of conjugated estrogens/ bazedoxifene (CE/ BZA) on the mood (depression and anxiety) in peri- and early menopausal women.


Eligibility

Sex: FEMALEMin Age: 45 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study looks at whether a hormone therapy called Duavive (a combination of estrogen and a bone-protective compound) can help improve mood and reduce anxiety in women going through perimenopause or early menopause who are experiencing depression or anxiety symptoms. **You may be eligible if...** - You are a woman between 45 and 60 years old - You are in perimenopause or within 10 years of your last menstrual period - You are experiencing symptoms of depression and/or anxiety - You can communicate in English **You may NOT be eligible if...** - You have a history of breast, ovarian, or endometrial cancer - You have unexplained abnormal uterine bleeding - You have had a blood clot, stroke, or heart attack - You have active liver disease - You have a known blood clotting disorder Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDuavive 0.45Mg-20Mg Tablet

Duavee, marketed as Duavive in Canada.


Locations(1)

St Joseph's Healthcare

Hamilton, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04478305


Related Trials